S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

Cardiol Therapeutics (CRDL) Competitors

C$2.65
-0.18 (-6.36%)
(As of 03/1/2024 ET)

CRDL vs. HLS, CPH, ACB, OGI, WEED, GUD, EDT, SVA, ONC, and HTL

Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include HLS Therapeutics (HLS), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), Organigram (OGI), Canopy Growth (WEED), Knight Therapeutics (GUD), Spectral Medical (EDT), Sernova (SVA), Oncolytics Biotech (ONC), and Hamilton Thorne (HTL). These companies are all part of the "medical" sector.

Cardiol Therapeutics vs.

Cardiol Therapeutics (TSE:CRDL) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Cardiol Therapeutics has higher earnings, but lower revenue than HLS Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$28.01M-C$0.43-6.16
HLS TherapeuticsC$62.89M2.14-C$28.56M-C$1.19-3.53

HLS Therapeutics has a consensus price target of C$10.28, suggesting a potential upside of 144.84%. Given HLS Therapeutics' higher possible upside, analysts clearly believe HLS Therapeutics is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
HLS Therapeutics
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.00 beat HLS Therapeutics' score of -0.35 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cardiol Therapeutics Neutral
HLS Therapeutics Neutral

Cardiol Therapeutics has a net margin of 0.00% compared to HLS Therapeutics' net margin of -45.41%. HLS Therapeutics' return on equity of -24.49% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -59.88% -34.61%
HLS Therapeutics -45.41%-24.49%-3.58%

13.7% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 59.7% of HLS Therapeutics shares are held by institutional investors. 4.1% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 3.1% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HLS Therapeutics received 26 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 73.91% of users gave HLS Therapeutics an outperform vote while only 66.67% of users gave Cardiol Therapeutics an outperform vote.

CompanyUnderperformOutperform
Cardiol TherapeuticsOutperform Votes
8
66.67%
Underperform Votes
4
33.33%
HLS TherapeuticsOutperform Votes
34
73.91%
Underperform Votes
12
26.09%

Cardiol Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Summary

HLS Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.


Get Cardiol Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDL vs. The Competition

MetricCardiol TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$172.54MC$1.12BC$5.02BC$5.13B
Dividend YieldN/A2.97%2.81%5.65%
P/E Ratio-6.161,456.79259.4622.95
Price / SalesN/A9,907.373,041.131,299.59
Price / Cash0.9810.0097.8979.49
Price / Book4.913.374.592.75
Net Income-C$28.01MC$116.07MC$114.85MC$290.22M
7 Day Performance21.56%1.58%5.63%1.77%
1 Month Performance64.60%7.63%10.42%2.57%
1 Year Performance273.24%10.16%13.93%3.93%

Cardiol Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HLS
HLS Therapeutics
0.9458 of 5 stars
C$3.98
+5.3%
C$10.28
+158.4%
-50.8%C$127.64MC$62.89M-3.3499High Trading Volume
CPH
Cipher Pharmaceuticals
0 of 5 stars
C$7.62
+5.2%
C$8.00
+5.0%
+91.0%C$183.03MC$21.15M4.485High Trading Volume
ACB
Aurora Cannabis
0.1494 of 5 stars
C$4.49
+3.2%
C$2.26
-49.6%
+281.4%C$244.89MC$275.88M-0.061,338Analyst Report
High Trading Volume
OGI
Organigram
2.7445 of 5 stars
C$2.91
+5.8%
C$3.39
+16.3%
+185.3%C$273.83MC$149.21M-1.16923Analyst Report
WEED
Canopy Growth
0.2059 of 5 stars
C$4.80
+1.7%
C$3.20
-33.3%
+41.7%C$437.33MC$362.24M-0.232,700Analyst Report
GUD
Knight Therapeutics
1.2663 of 5 stars
C$5.57
+1.5%
C$5.92
+6.2%
+8.4%C$581.29MC$335.66M-92.83698Analyst Report
Analyst Revision
News Coverage
EDT
Spectral Medical
0 of 5 stars
C$0.53
-3.6%
N/A+80.6%C$147.65MC$1.79M-10.6032
SVA
Sernova
1.6499 of 5 stars
C$0.62
-3.1%
C$6.00
+867.7%
-40.0%C$188.07MN/A-4.771,959
ONC
Oncolytics Biotech
0.5875 of 5 stars
C$1.43
+7.5%
C$9.00
+529.4%
-27.8%C$104.96MN/A-2.8029News Coverage
HTL
Hamilton Thorne
0 of 5 stars
C$1.31
-0.8%
N/AN/AC$198.94MC$65.21M43.67N/AGap Up

Related Companies and Tools

This page (TSE:CRDL) was last updated on 3/2/2024 by MarketBeat.com Staff